MNPR FY2026 EPS Estimate Lifted by Brookline Capital Markets

Key Points

• Brookline Capital Markets raised Monopar Therapeutics’ FY2026 EPS forecast to a loss of $2.70 per share from a previous estimate of $2.88, compared with the $2.96 consensus estimate.
• Monopar reported a quarterly loss of $0.62 per share, beating analysts’ expected loss of $0.64 per share by $0.02.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus rating and an average price target of $118.67; MNPR opened at $123.84 and has gained significantly from its 52-week low of $29.18.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at Brookline Capital Markets lifted their FY2026 EPS estimates for Monopar Therapeutics in a note issued to investors on Monday, August 17th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($2.70) for the year, up from their previous estimate of ($2.88). The consensus estimate for Monopar Therapeutics' current full-year earnings is ($2.96) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics' Q4 2026 earnings at ($0.81) EPS.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.02.

MNPR has been the subject of a number of other research reports. Cantor Fitzgerald downgraded Monopar Therapeutics from an "overweight" rating to a "neutral" rating and raised their price objective for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. Morgan Stanley reaffirmed an "overweight" rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday. Barclays reiterated an "overweight" rating and issued a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a research report on Thursday, August 13th. BTIG Research boosted their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Finally, HC Wainwright increased their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the company a "buy" rating in a research report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $118.67.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $123.84 on Thursday. The firm has a fifty day moving average price of $99.68 and a two-hundred day moving average price of $72.61. Monopar Therapeutics has a fifty-two week low of $29.18 and a fifty-two week high of $124.82. The firm has a market cap of $830.97 million, a price-to-earnings ratio of -57.07 and a beta of 1.47.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics in the third quarter valued at about $28,000. BNP Paribas Financial Markets grew its holdings in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock valued at $57,000 after buying an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics in the 4th quarter valued at $65,000. Caitong International Asset Management Co. Ltd bought a new position in Monopar Therapeutics during the 4th quarter worth $86,000. Finally, JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after buying an additional 1,821 shares during the period. Institutional investors and hedge funds own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source